MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on April 21, 2008; DOI: 10.1124/mol.108.045278


0026-895X/08/7401-236-245$20.00
Mol Pharmacol 74:236-245, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
mol.108.045278v1
74/1/236    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Park, Y.-K.
Right arrow Articles by Park, H.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Park, Y.-K.
Right arrow Articles by Park, H.

Nitric Oxide Donor, (±)-S-Nitroso-N-acetylpenicillamine, Stabilizes Transactive Hypoxia-Inducible Factor-1{alpha} by Inhibiting von Hippel-Lindau Recruitment and Asparagine HydroxylationFormula

Young-Kwon Park, Dae-Ro Ahn, Myoungsuk Oh, Taekyoung Lee, Eun Gyeong Yang, Miwon Son, and Hyunsung Park

Department of Life Science, University of Seoul, Seoul, Korea (Y.-K.P., M.O., T.L., H.P.); Life Science Division, Korea Institute of Science and Technology, Seoul, Korea (D.-R.A., E.G.Y.); and Research Labs of Dong-A Pharm. Co. Ltd., Kyunggi-do, Korea (M.S.)

We have confirmed that the NO donor (±)-S-nitroso-N-acetylpenicillamine (SNAP) stabilizes the transactive form of hypoxia-inducible factor-1{alpha} (HIF-1{alpha}), leading to the induction of HIF-1{alpha} target genes such as vascular endothelial growth factor and carbonic anhydrase 9. Activation of HIF-1{alpha} should require inhibition of the dual system that keeps it inactive. One is ubiquitination, which is triggered by hydroxylation of HIF-1{alpha}-proline and the subsequent binding of E3 ubiquitin ligase, the von Hippel Lindau (VHL) protein. The other is hydroxylation of HIF-1{alpha}-asparagine, which reduces the affinity of HIF-1{alpha} for its coactivator, cAMP responsive element binding protein/p300. We examined the effects of the NO donor SNAP on proline and asparagine hydroxylation of HIF-1{alpha} peptides by measuring the activities of the corresponding enzymes, HIF-1{alpha}-specific proline hydroxylase 2 (PHD2) and the HIF-1{alpha}-specific asparagine hydroxylase, designated factor inhibiting HIF-1{alpha} (FIH-1), respectively. We found that the SNAP did not prevent PHD2 from hydroxylating the proline of HIF-1{alpha}. Instead, it blocked the interaction between VHL and the proline-hydroxylated HIF-1{alpha}, but only when the reducing agents Fe(II) and vitamin C were limiting. The fact that the absence of cysteine 520 of HIF-1{alpha} abolishes its responsiveness to SNAP suggests that this residue mediates the inhibition by SNAP of the interaction between VHL and HIF-1{alpha}, presumably by S-nitrosylation of HIF-1{alpha}. Un-like PHD2, asparagine hydroxylation by FIH-1 was directly inhibited by SNAP, but again only when reducing agents were limiting. Substitution of cysteine 800 of HIF-1{alpha} with alanine failed to reverse the inhibitory effects of SNAP on asparagine hydroxylation, implying that FIH-1, not its substrate HIF-1{alpha}, is inhibited by SNAP.


Received January 14, 2008; accepted April 21, 2008

Address correspondence to: Dr. Hyunsung Park, 90 Cheonnong-dong, Tongdaemun-gu, Seoul, 130-743, Republic of Korea. E-mail: hspark{at}uos.ac.kr







Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics